October 7, 2024
Photo Credit: Getty Images
HAINAN ISLAND, China — At the 19th International Myopia Conference, HOYA Vision Care shared the eight-year results from its ongoing clinical trial. The study is evaluating the long-term myopia control effect and user experience in patients wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses.1 This is the longest clinical study conducted and presented on the MiYOSMART myopia management spectacle lenses worldwide.
In this study, 60% of the participants who wore DIMS spectacles for six years continued with DIMS spectacles for as long as eight years. All participants were satisfied with the benefits from the DIMS spectacle lenses, which raised their awareness of their own myopia management.
“With myopia on the rise, it is important for eye care professionals to choose treatments to slow the progression in children based on best evidence available,” said Professor Carly Lam, principal investigator of the study. “Previous research has shown that the DIMS spectacle lenses appear to be a safe and effective method for managing myopia among the study population. We’re looking forward to seeing the impact of longer-term use on myopia management in this pediatric population.”
Internationally, the defocus theory is the currently accepted theory for explaining induced myopia progression due to single-vision spectacle lenses. DIMS Technology forms the basis for myopia management with MiYOSMART. Through this exclusive non-invasive technology, the lens corrects the visual defect on its entire surface and has a ring-shaped treatment area to slow down myopia progression. The alternation of the focus area and defocus area provides clear vision and manages myopia simultaneously.2
“Childhood myopia is a widespread concern, and we are committed to continue fighting this problem, by using innovative solutions like MiYOSMART spectacle lenses. We look forward to the data from this important study as we continue to work to slow the progression of myopia in children and preserve their vision and eye health for the future,” said Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care.
Since its launch in 2018, more than eight million MiYOSMART spectacle lenses have already been sold worldwide in more than 35 countries and regions.3 HOYA Vision Care will continue bringing new evidence on the safety and effectiveness of MiYOSMART and share knowledge on myopia management to help combat and control the growing problem of myopia worldwide.
MiYOSMART lenses are not available in the United States.
References
1 Lam, CSY, el al. Eight Years of Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses: User Experience and Myopia Control Outcomes. Poster number B32. Presented 27th Sep, IMC 2024.
2 Lam CSY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. Brit Jour of Ophthalmol. Published Online First: 29 May 2019. doi: 10.1136/ bjophthalmol-2018-313739
3 Based on number of MiYOSMART spectacle lenses sold as per HOYA sales data on file as of July 2024.
